# Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/exenatide-once-weekly-plus-dapagliflozin-once-daily-versus-exenatide-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Juan P. Frías,Cristian Guja,Elise Hardy,Azazuddin Ahmed,Fang Dong,Peter Öhman,Serge Jabbour |
| Citations | 394 |
| DOI | 10.1016/s2213-8587(16)30267-4 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2519803668 |
| PMID | 27651331 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Cristian Guja](https://scholariq.org/researchers/cristian-guja/)

## Paper journal

- [The Lancet Diabetes & Endocrinology](https://scholariq.org/journals/the-lancet-diabetes-and-endocrinology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.